JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 37 No. 11 1850-1852
© 1996 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhawan, V.
Right arrow Articles by Eidelberg, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhawan, V.
Right arrow Articles by Eidelberg, D.

Bladder Wall Radiation Dose in Humans from Fluorine-18-FDOPA

Vijay Dhawan, Abdelfatihe Belakhlef, William Robeson, Tatsuya Ishikawa, Claude Margouleff, Shugo Takikawa, Thomas Chaly, Ken Kazumata, Donald Margouleff and David Eidelberg

Department of Neurology, Research and Medicine, North Shore University Hospital/Cornell University Medical College, Manhasset, New York

Correspondence: For correspondence or reprints contact: Dr. Vijay Dhawan, Department of Neurology, North Shore University Hospital/Cornell University Medical College, 350 Community Dr., Manhasset. NY 11030.

ABSTRACT

PET, in conjunction with 18F-fluorodopa (FDOPA), has become the standard technique to assess basal ganglia degeneration in patients with movement disorders. Based on published dosimetry data, the injected dose of FDOPA is limited to 111 Mbq (3 mCi) because of exposure to the bladder wall, which is the critical organ for such studies. These dosimetry studies are based on mathematical models for the bladder radioactivity accumulation and clearance when the subjects were asked to void approximately 2 hr after the intravenous injection of FDOPA. In this study, we improved the radiation dose estimate to the bladder wall using dynamic PET to image the bladder during the uptake phase as well as before and after voiding. Methods: The subjects were tested on a new protocol. They were hydrated preinjection and given a first bladder void break at 40 min postinjection and a second void at the end of study at 120 min. Results: The MIRD model, applied to the data collected from 10 adults of both sexes, yielded an average absorbed dose of 0.15 ± 0.08 mGy/MBq (0.57 ± 0.28 rad/mCi). Conclusion: This absorbed dose is significantly lower than previous estimates and allows for FDOPA injections up to 333 Mbq (9 mCi).

Key Words: PET • fluorine-18-FDOPA • dosimetry




This article has been cited by other articles:


Home page
JNMHome page
W. Robeson, V. Dhawan, A. Belakhlef, Y. Ma, V. Pillai, T. Chaly, C. Margouleff, D. Bjelke, and D. Eidelberg
Dosimetry of the Dopamine Transporter Radioligand 18F-FPCIT in Human Subjects
J. Nucl. Med., June 1, 2003; 44(6): 961 - 966.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1996 by the Society of Nuclear Medicine.